Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 1
2003 1
2006 2
2007 1
2008 2
2010 1
2011 2
2012 9
2013 8
2014 1
2015 4
2016 2
2017 9
2018 6
2019 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

50 results
Results by year
Filters applied: . Clear all
Page 1
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. DeNardo DG, et al. Among authors: Madden SF. Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1. Cancer Discov. 2011. PMID: 22039576 Free PMC article.
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O'Connor DP, Gallagher WM. Li B, et al. Among authors: Madden SF. Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28. Cancer Res. 2017. PMID: 28455421 Free article.
MicroRNA-22 Controls Aberrant Neurogenesis and Changes in Neuronal Morphology After Status Epilepticus.
Beamer EH, Jurado-Arjona J, Jimenez-Mateos EM, Morgan J, Reschke CR, Kenny A, de Leo G, Olivos-Oré LA, Arribas-Blázquez M, Madden SF, Merchán-Rubira J, Delanty N, Farrell MA, O'Brien DF, Avila J, Diaz-Hernandez M, Miras-Portugal MT, Artalejo AR, Hernandez F, Henshall DC, Engel T. Beamer EH, et al. Among authors: Madden SF. Front Mol Neurosci. 2018 Dec 11;11:442. doi: 10.3389/fnmol.2018.00442. eCollection 2018. Front Mol Neurosci. 2018. PMID: 30618601 Free PMC article.
Vitamin D receptor as a target for breast cancer therapy.
Murray A, Madden SF, Synnott NC, Klinger R, O'Connor D, O'Donovan N, Gallagher W, Crown J, Duffy MJ. Murray A, et al. Among authors: Madden SF. Endocr Relat Cancer. 2017 Apr;24(4):181-195. doi: 10.1530/ERC-16-0463. Epub 2017 Feb 17. Endocr Relat Cancer. 2017. PMID: 28213567
Bidirectional KCNQ1:β-catenin interaction drives colorectal cancer cell differentiation.
Rapetti-Mauss R, Bustos V, Thomas W, McBryan J, Harvey H, Lajczak N, Madden SF, Pellissier B, Borgese F, Soriani O, Harvey BJ. Rapetti-Mauss R, et al. Among authors: Madden SF. Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4159-4164. doi: 10.1073/pnas.1702913114. Epub 2017 Apr 3. Proc Natl Acad Sci U S A. 2017. PMID: 28373572 Free PMC article.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J. Eustace AJ, et al. Among authors: Madden SF. BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1. BMC Cancer. 2018. PMID: 30305055 Free PMC article.
Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.
Muliaditan T, Opzoomer JW, Caron J, Okesola M, Kosti P, Lall S, Van Hemelrijck M, Dazzi F, Tutt A, Grigoriadis A, Gillett CE, Madden SF, Burchell JM, Kordasti S, Diebold SS, Spicer JF, Arnold JN. Muliaditan T, et al. Among authors: Madden SF. Clin Cancer Res. 2018 Apr 1;24(7):1617-1628. doi: 10.1158/1078-0432.CCR-17-2587. Epub 2018 Jan 16. Clin Cancer Res. 2018. PMID: 29339440 Free PMC article.
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Milewska M, Cremona M, Morgan C, O'Shea J, Carr A, Vellanki SH, Hopkins AM, Toomey S, Madden SF, Hennessy BT, Eustace AJ. Milewska M, et al. Among authors: Madden SF. Ther Adv Med Oncol. 2018 Jan 9;10:1758834017746040. doi: 10.1177/1758834017746040. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29383036 Free PMC article.
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ. O'Shea J, et al. Among authors: Madden SF. Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156708 Free PMC article.
50 results
Jump to page
Feedback